Cardiac Amyloidosis: On the Road

Multimodality Imaging for the Evaluation & Management of Cardiac Amyloidosis Live Program
Saturday, December 11, 2021


Credits: Earn 2.75* AMA PRA Category 1 Credits™​  

*Credits subject to change

Program Director: 
Fadi Hage, MD, MASNC

 

Agenda

December 11, 2021: Multimodality Imaging for the Evaluation & Management of Cardiac Amyloidosis 
Time (CT) Title Speaker
7:55 am Welcome Fadi Hage, MD, MASNC
8:00 am Cardiac Amyloid Case Presentation Stephen Clarkson, MD
8:10 am When to suspect cardiac amyloid?  Carrie Lenneman, MD
8:30 am Echocardiographic imaging for cardiac amyloid Riem Hawi, MD
8:50 am MRI for cardiac amyloid Steven Lloyd, MD
9:10 am Discussion and Q&A Fadi Hage, MD, MASNC and faculty
9:20 am Break
9:30 am Cardiac Amyloid Case Presentation Nikky Bardia, MD
9:40 am Technetium-99m Pyrophosphate (PYP) Imaging for cardiac amyloid Fadi Hage, MD, MASNC
10:00 am Pathways for management of patients with equivocal PYP imaging Pradeep Bhambhvani, MD
10:20 am Cardiac Amyloid Case Presentation Jordan Gunn, MD
10:30 am Clinical management of cardiac amyloid Jose Tallaj, MD
10:50 am Discussion and Q&A Fadi Hage, MD, MASNC and faculty
11:05 am Wrap up  Fadi Hage, MD, MASNC


The Cardiac Amyloidosis: On the Road programs will:

  • Address the knowledge, competence and performance gaps in disease epidemiology, pathophysiology, diagnosis and treatments for ATTR-CM. 

  • Improve diagnosis across all patient populations, timely referral to amyloid experts, and knowledge of treatment options with the goal of improving outcomes of patients with ATTR-CM. 

  • Enhance the understanding of the overlap of cardiac amyloidosis with other conditions leading to a misdiagnosis or delayed diagnosis.  

  • Focus on the diagnostic algorithm, including the appropriate use of Tc-99m PYP, and the importance of image interpretation alongside other clinical findings. 

  • Discuss the central role of Tc-99m PYP imaging and the protocols for acquisition, processing and interpretation to ensure understanding of the procedure and the data it provides.

Participants of these programs will be able to:

  • Describe amyloidosis, including specific types, cardiac features and disease burden.

  • Identify barriers to identification and diagnosis of patients suspected of ATTR.

  • Recognize patients at risk for hereditary ATTR (hATTR) and wild-type ATTR (wtATTR).

  • Summarize the diagnostic evaluation for cardiac amyloidosis including the differential diagnosis. 

  • Provide details of Tc-99m PYP including imaging protocol, semi-quantitative and quantitative scoring, interpretation including identifying false positive and false negative studies, and components of an appropriate report. 

  • Demonstrate understanding of current treatments for patients with ATTR-CM.

If you have any questions about registration, please contact info@asnc.org

These programs are supported by educational grants from Pfizer.
 

More Cardiac Amyloidosis Resources


Back to top